Day: March 27, 2023

Posted on

FeedbackFruits Launches the Enhanced Version of Their Team Based Learning Tool for Digitizing Collaboration

The new Team Based Learning tool aims to drive student engagement and collaboration through streamlining team-based learning across modalities.

AMSTERDAM, NETHERLANDS / ACCESSWIRE / March 27, 2023 / FeedbackFruits has released the new Team Based Learning, an LMS-integrated tool designed to digitize and scale collaborative learning across all course sizes and modalities.

Related Image

Team Based Learning supports and enhances the facilitation of the entire team-based learning (TBL) process, a collaborative learning approach that gives students the possibility to apply their knowledge to solve single or multiple problems.

The development of the tool was initiated in collaboration with Deakin University and IE Business School, where TBL is one of the prominent pedagogical approaches. Both institutions wanted to develop an easy-to-use, LMS-integrated tool to accommodate different elements of TBL. The initial version of the tool was launched to help automate the individual Readiness Assurance Test (iRAT) and team Readiness Assurance Test (tRAT). FeedbackFruits then continued to work with Deakin University over the past year to further expand the tool’s capacity to cover all the major steps of the TBL process.

The new Team Based Learning presents several functionalities that support and optimize each stage of the TBL process. With the ability to add engaging pre-work assignments, adjust activity timing, decide on group representatives, and configure peer evaluation steps, instructors can streamline a complete collaborative activity in any modality. At the same time, students enjoy a meaningful learning experience where collaboration, autonomy, and accountability are maintained.

Dr. Svetlana Stevanovic emphasized the tool’s capacity for facilitating meaningful collaborative activities:

“I used FeedbackFruits for my first-year unit. The unit has a team-based learning component where students are expected to collaborate to reach a consensus on a specific topic/research question. They are required to do some reading before the class. The unit runs online and in person. I used Team Based Learning to facilitate peer assessment and integrate the quiz into the studio. The enrollment process worked well and enabled students to participate in groups. Students were actively engaged and liked the classes.”

For Joost Verdoorn, Chief Product Officer of FeedbackFruits, the launch marks an exciting chapter in the company’s story of driving effective pedagogy: “With this release, we show that FeedbackFruits is dedicated to supporting innovative and proven teaching methods, allowing students worldwide to enjoy better and more meaningful learning experiences.”

Since its first iteration, the tool has been adopted at 39 institutions worldwide and helped faculties create 197 courses with 865 TBL activities.

About FeedbackFruits

FeedbackFruits is an EdTech scale-up based in Amsterdam whose mission is to drive student engagement while increasing teacher productivity. The platform encompasses a range of learning activities such as self & peer assessment, online discussion, and team-based learning. The company is currently supporting over 100 institutions worldwide with 90+ employees.

For more information, press only: marketing@feedbackfruits.com

Contact Information

Irmak Ozgenoglu
Marketing Manager
irmak@feedbackfruits.com

SOURCE: FeedbackFruits

Posted on

Zoom announces the expansion of Zoom IQ, the smart companion that empowers collaboration and unlocks potential

Zoom uses OpenAI technologies to bolster a unique federated approach to AI based on flexibility

SAN JOSE, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Today at Enterprise Connect, Zoom Video Communications, Inc. (NASDAQ: ZM) announced the expansion of Zoom IQ, a smart companion that empowers collaboration and unlocks people’s potential by summarizing chat threads, organizing ideas, drafting content for chats, emails, and whiteboard sessions, creating meeting agendas, and more. The company also announced it will use OpenAI to bolster its unique federated approach to AI based on flexibility.

Zoom’s federated approach to AI leverages its own proprietary AI models, those from leading AI companies– such as OpenAI –and select customers’ own models. With this flexibility to incorporate multiple types of models, Zoom’s goal is to provide the most value for its customers’ diverse needs. These models can also be customized to perform better for a customer, based on their vocabulary and requirements.

“Zoom has long built AI solutions into our products to empower customers to be more productive,” said Smita Hashim, chief product officer at Zoom. “We are excited to bring many more capabilities with new large language models. Our unique approach to AI will give customers the flexibility they want and help significantly improve collaboration and customer relations.”

In today’s work environment, workers find it increasingly difficult to balance workday priorities between emails, team chats, meetings, and project management tasks. Teams are also looking for ways to better co-create effectively in real-time. To help solve these challenges, Zoom IQ will have a host of new capabilities scheduled to release soon, including:

  • Zoom IQ chat compose: Zoom Team Chat users can soon use the compose feature to help compose messages based on conversational context in addition to changing message tone to customize suggested responses.
  • Zoom IQ email compose: Harnessing the power of Generative AI, users will get email draft suggestions in response to the conversational context from prior Zoom Meetings, Zoom Phone calls, and email threads. Available initially in Zoom IQ for Sales.
  • Zoom IQ meeting summary: Generate a summary, capture next steps, and share via Team Chat, Zoom Calendar, and email without recording the conversation, so those who didn’t attend will no longer have to sit through lengthy recordings.

Additionally at Enterprise Connect, Zoom is showcasing the following innovations to make teamwork more meaningful and strengthen customer relationships:

  • Zoom Huddles (formerly Zoom Spots) is a new video-enabled virtual coworking space designed to foster ad-hoc discussions and relationship building, to replicate the “working alongside” aspect of an open office and encourage free-form video-first conversations. Zoom Huddles is now available globally for customers to request early access by visiting the product page.
  • Intelligent Director uses multiple cameras in a Zoom Room to determine the best angle of the individuals in the room to display within the meeting. With high-quality, reliable video and voice, Intelligent Director also provides a best-in-class experience for remote participants. Available in beta soon.
  • Zoom Scheduler makes it easy to find the perfect time for meetings by sharing the host’s availability so others (even external participants) can conveniently book appointments. Zoom Scheduler reduces the back-and-forth hassle of manual scheduling by placing a meeting on the host’s calendar with a Zoom Meetings link already included, saving both participants time. Zoom Scheduler works seamlessly with Zoom Meetings and Zoom Mail and Calendar, and integrates with Google Calendar and Microsoft 365, so hosts can use their preferred calendar.

Additional Resources:

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Beth McLaughlin
press@zoom.us

GlobeNewswire Distribution ID 8795878

Posted on

bioLytical Laboratories Inc. Receives Health Canada Authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test

bioLytical Laboratories Inc. announced today that it has launched its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test for professional use in Canada

INSTI® Multiplex HIV-1/2 Syphilis Antibody Test

INSTI® Multiplex HIV-1/2 Syphilis Antibody Test Package

  • bioLytical has received Health Canada authorization to sell its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test across Canada for professional use in point-of-care settings
  • By providing results for two infections with only one sample, the test helps reduce test anxiety for patients by allowing healthcare professionals to test more people in less time
  • The test is portable and can be performed in a multitude of settings with easy-to-understand results
  • As part of the Health Canada review and authorization, the submission included clinical data from the two-year PoSH Study led by researchers at the University of Alberta and St. Michael’s Hospital, a site of Unity Health Toronto
  • Test performance in clinical studies demonstrated high accuracy, with industry-leading sensitivity and specificity
  • bioLytical’s quality system is MDSAP: ISO 13485 certified

RICHMOND, British Columbia, March 27, 2023 (GLOBE NEWSWIRE) — bioLytical Laboratories Inc. (“bioLytical”), a global leader in rapid in-vitro medical diagnostics, announced today that it has received Health Canada authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test, allowing its immediate entry into the Canadian market. Furthermore, bioLytical is working on a self-test version to ensure Canadians of all demographics can access regular and early testing for both infections, where and when it works best for them.

“I am proud to lead a team of hardworking and innovative individuals who consistently push the boundaries of what is possible,” says Rob Mackie, CEO of bioLytical. “Our continued dedication to excellence allowed us to achieve this remarkable milestone that will help Canadians across all demographics access early testing in various settings.”

As a well-known leader in global HIV testing with its innovative INSTI® HIV-1/2 Antibody Test, authorized by Health Canada for both professional and self-testing use, bioLytical has leveraged its proprietary INSTI® technology to develop the INSTI® Multiplex HIV-1/2 Syphilis Antibody Test, first approved and in use across Europe and Africa since 2016.

The test is designed to detect both HIV-1/2 and syphilis antibodies with one sample using a simple fingerprick method to deliver accurate results in one minute or less. Mobile and simple to use, INSTI® allows healthcare professionals to test in various environments, providing flexible options for persons that face barriers to accessing healthcare.

As part of Health Canada’s review and subsequent authorization, the two-year Point of Care Tests for Syphilis and HIV (PoSH) Study, completed between August 2020 and February 2022, was included in the submission process. The Study, led by researchers at the University of Alberta and St. Michael’s hospital, a site of Unity Health Toronto, showcased the importance of regular and frequent testing to help connect patients to care. Due to the real-time results that the innovative INSTI® platform provides, those who tested positive for HIV were either linked or relinked to care, and of those that tested positive for active syphilis, the majority (87.4%) were treated immediately following point-of-care test results, and the remaining participants were treated within a median of four days.

Syphilis is a serious health issue that can lead to long-term health consequences if left untreated. Canada is currently experiencing unprecedented syphilis infection rates, with a 166% nationwide increase from 2017-2021. Rates have increased across all demographics, with new infections increasing by 20% between 2020 and 2021 despite decreased access to STBBI services during the pandemic. Furthermore, there is a growing concern about increasing congenital syphilis, with a 1271% increase in the same period.

With an estimated 62,790 persons living with HIV (PLWH) in Canada and with an estimated 1,520 new HIV infections annually, co-infection with syphilis and HIV is a growing concern. While both infections can affect anyone, having a STI such as syphilis increases the chance of acquiring HIV and in PLWH, increases the chances of passing on HIV. Additionally, syphilis sores or ulcers can allow HIV and other STIs to enter the body.

Rapid testing is instrumental in ending HIV and syphilis as public health threats. Regular and early access to testing allows medical professionals to offer early interventions by quickly connecting patients to care and support, reducing onward transmission, and increasing awareness of prevention methods.

If syphilis is diagnosed within a year of infection, it can usually be treated with a single injection of medication. HIV treatment has also progressed significantly since the virus was identified over 40 years ago, allowing persons living with HIV to lead long and healthy lives on treatment. Creating a test that can identify both infections with a single sample helps ensure that Canadians can connect to care quickly and equitably. The INSTI® Multiplex HIV-1/2 Syphilis Antibody Test is an innovative and efficient approach to increasing access to early and regular testing for sexually transmitted and blood-borne infections (STBBIs) in Canada.

“With the rise of syphilis in Canada, including the concerning increase in congenital syphilis, there is an urgent need for a fast and reliable rapid diagnostic test,” said Mackie. “With the development of a highly accurate and innovative one-minute test, INSTI® allows Canadians to learn their status to two infections with only one drop of blood, helping more Canadians access testing, learn their status, and connect to care.”

bioLytical will manufacture the INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in its MDSAP: ISO 13485-certified facility in British Columbia to sell and distribute across Canada. As a global leader in ultra-rapid infectious disease diagnostics, bioLytical is working to ensure our test kits are available to Canadians so they can know their status.

bioLytical Laboratories Inc. is a privately-owned Canadian company focused on researching, developing, and commercializing rapid in-vitro medical diagnostics using its proprietary INSTI® technology platform and its lateral flow line, iStatis. bioLytical has won several local and industry awards, including B.C. Exporter of the Year in 2019. We have been named Lifesciences B.C.’s Growth Stage Med Tech Company of the Year and featured on B.C.’s Fastest-Growing Companies for six years, including the Globe and Mail’s Fastest Growing Companies list in 2020. bioLytical moved to a significantly larger, state-of-the-art facility in Richmond, B.C., in 2020 to accommodate the extraordinary growth achieved through our team. Providing accurate results in one minute or less, the INSTI® range includes the INSTI® HIV-1/HIV-2 Antibody Test, INSTI® Multiplex HIV Syphilis Ab Test, INSTI® HIV Self Test, INSTI® Covid-19 Antibody Test, and the INSTI® HCV Antibody Test. bioLytical sells its products in Europe, North America, South America, Africa, and Asia. In 2022, bioLytical launched iStatis, its new lateral flow testing platform, to create additional access to testing worldwide.

By delivering accurate results in real-time, INSTI® and iStatis generate meaningful outcomes for medical professionals, patients, and public health organizations worldwide and is a key partner in tackling some of the world’s most severe healthcare challenges. Please visit www.istatis.com and www.insti.com, and www.biolytical.com for more information.

References

CATIE: https://www.catie.ca/syphilis-0
PHAC: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-11-12-november-december-2022/infectious-congenital-syphilis-canada-2021.html
PHAC: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4adaf035-89ca-428d-a01d-9bf5c3f05e4b

Media Contact
Stephanie Ritchie, Communications Specialist, bioLytical
press@biolytical.com
+1-778-238-9340

GlobeNewswire Distribution ID 8795504

Posted on

‫وزارة الصحة الكندية تمنح تصريحًا لشركة bioLytical Laboratories Inc. لاختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis

أعلنت شركة bioLytical Laboratories Inc. اليوم أنها أطلقت اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis وأنه أصبح متاحًا للاستخدام من قبل المتخصصين في كندا.

  • حصلت bioLytical على تصريح من وزارة الصحة الكندية لطرح اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis للبيع في جميع أنحاء كندا لاستخدامه من قبل المتخصصين في مرافق الرعاية الصحية
  • يقلل الاختبار من القلق لدى المرضى حيال إجراء الاختبارات حيث يتيح لأخصائيي الرعاية الصحية اختبار المزيد من الأشخاص في وقت أقل من خلال تقديم النتائج بخصوص اثنتين من العدوى باستخدام عينة واحدة فقط
  • الاختبار سهل الحمل ويمكن إجراؤه في العديد من الأماكن مع نتائج سهلة الفهم
  • وفي إطار المراجعة التي أجرتها وزارة الصحة الكندية ومنحها التصريح، تضمَّنت الوثائق المقدمة بيانات سريرية مستقاة من دراسة (PoSH) التي استغرقت عامين وأُجريت بقيادة باحثين في جامعة ألبرتا ومستشفى سانت مايكل وهو أحد المواقع التابعة لـ Unity Health Toronto
  • أظهر اختبار الأداء في الدراسات السريرية دقة عالية، مع حساسية وتخصصية رائدتين في الصناعة
  • نظام الجودة في bioLytical هو (MDSAP): حاصل على شهادة الجودة أيزو ISO 13485

ريتشموند، كولومبيا البريطانية، 27 مارس/آذار 2023 (GLOBE NEWSWIRE) – أعلنت شركة bioLytical Laboratories Inc. (“bioLytical”)، الشركة العالمية الرائدة في مجال التشخيص الطبي السريع في المختبرات، اليوم حصولها على تصريح من وزارة الصحة الكندية بخصوص اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis لديها، ما يسمح بدخولها الفوري إلى السوق الكندية. بالإضافة إلى ذلك، تعمل bioLytical على تقديم إصدار اختبار ذاتي لضمان إمكانية حصول الكنديين من جميع الفئات السكانية على الاختبارات المنتظمة والمبكرة لكلتا العدوى، في أي وقت وفي أي مكان يكون فيه أكثر ملاءمة لهم.

صرَّح Rob Mackie، الرئيس التنفيذي لشركة bioLytical، قائلًا “أنا فخور بقيادة فريق من الأشخاص المتفانين والمبدعين الذين يوسعون آفاق ما هو ممكن على الدوام”، وأردف قائلًا “إن التزامنا المستمر بتحقيق التميز هو ما مكننا من الوصول إلى هذا الإنجاز الرائع الذي سيساعد الكنديين من جميع الفئات السكانية على إجراء الاختبارات المبكرة في مختلف الأماكن.”

ولكونها شركة رائدة معروفة في ميدان اختبارات فيروس نقص المناعة البشرية على مستوى العالم بفضل اختبار الأجسام المضادة المبتكر INSTI® HIV-1/2 المصرح به من قبل وزارة الصحة الكندية للاستخدام من قبل المتخصصين ولأغراض الاختبار الذاتي، استفادت شركة bioLytical من تقنية INSTI® لابتكار اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis الذي تمت الموافقة عليه لأول مرة ويجري استخدامه في أوروبا وأفريقيا منذ عام 2016.

الهدف من الاختبار هو اكتشاف كل من الأجسام المضادة لفيروس نقص المناعة البشرية-1/2 والزهري من خلال عينة واحدة باستخدام طريقة وخز الإصبع البسيطة للحصول على نتائج موثوقة في دقيقة واحدة أو أقل. تتيح INSTI® لأخصائي الرعاية الصحية إجراء الاختبار في مختلف البيئات بفضل قابلية نقله وسهولة استخدامه، الأمر الذي يوفر خيارات مرنة للأشخاص الذين يواجهون صعوبة في الحصول على خدمات الرعاية الصحية.

وفي إطار المراجعة التي أجرتها وزارة الصحة الكندية ومنحها التصريح فيما بعد، تضمنت الوثائق المقدمة دراسة اختبار نقطة الرعاية لمرض الزهري وفيروس نقص المناعة البشرية (PoSH) التي أجريت في الفترة ما بين أغسطس 2020 وفبراير 2022. أظهرت الدراسة – التي أُجريت بقيادة باحثين في جامعة ألبرتا ومستشفى سانت مايكل وهو أحد المواقع التابعة لـUnity Health Toronto، أهمية الاختبارات المنتظمة والمتكررة كوسيلة لتسهيل وصول المرضى إلى خدمات الرعاية. وبفضل النتائج الفورية التي توفرها منصة INSTI® المبتكرة، فقد تم توصيل الأشخاص الذين ثبتت إصابتهم بفيروس نقص المناعة البشرية بخدمات الرعاية أو إعادة إيصالهم بها؛ وأما الأشخاص الذين ثبتت إصابتهم بمرض الزهري النشط، فقد تلقى غالبيتهم (87.4٪) العلاج على الفور بعد نتائج اختبار نقطة الرعاية، وتلقى باقي المشاركين العلاج غضون أربعة أيام في المتوسط.

يُعد مرض الزهري من المشكلات الصحية الخطيرة التي يمكن أن تؤدي إلى آثار طويلة المدى على الصحة إذا تُركت دون علاج. تشهد كندا حاليًا معدلات غير مسبوقة للإصابة بمرض الزهري، حيث ارتفعت بنسبة 166٪ من عام 2017 إلى عام 2021 على الصعيد الوطني. وارتفعت معدلات الإصابة في جميع الفئات السكانية، مع زيادة الإصابات الجديدة بنسبة 20٪ بين عامي 2020 و2021 في ظل انخفاض الوصول إلى خدمات العدوى المنقولة جنسياً والعدوى المنقولة عن طريق الدم أثناء جائحة كورونا. علاوة على ذلك، زادت حالات الإصابة بمرض الزهري الخلقي بنسبة 1271٪ خلال نفس الفترة، مما يسبب أيضًا قلقًا متزايدًا.

تشكِّل الإصابة بمرض الزهري وفيروس نقص المناعة البشرية في آن واحد مصدر قلق متزايد بالنظر إلى أن هناك ما يقدر بـ 62,790 شخصًا مصابًا بفيروس نقص المناعة البشرية في كندا وأن هناك ما يقرب من 1,520 حالة إصابة جديدة بفيروس نقص المناعة البشرية كل عام. وفي حين أن كلتا العدوتين يمكن أن تصيبا أي شخص، فإن الإصابة بعدوى منقولة جنسيًا مثل مرض الزهري تزيد من خطر الإصابة بفيروس نقص المناعة البشرية، فضلًا عن أنها تزيد من خطر انتقال فيروس نقص المناعة البشرية لدى المصابين بهذا الفيروس. من جانب آخر، يمكن لفيروس نقص المناعة البشرية وغيره من العدوى المنقولة جنسيًا أن يتسلل إلى الجسم من خلال القروح التي يسببها مرض الزهري.

ويعتبر الاختبار السريع ضروريًا للقضاء على مرض الزهري وفيروس نقص المناعة البشرية باعتبارهما من المخاطر التي تهدد على الصحة العامة. يتيح إجراء الاختبار بصورة منتظمة ومبكرة للمتخصصين في المجال الطبي تقديم التدخلات المبكرة عن طريق إيصال المرضى بخدمات الرعاية والدعم على وجه السرعة، والحد من انتقال العدوى، وزيادة الوعي بطرق الوقاية.

هذا ويمكن علاج مرض الزهري عادةً بحقنة بسيطة من الدواء إذا تم تشخيصه في غضون عام من الإصابة. وعلى الجانب الآخر، شهد علاج فيروس نقص المناعة البشرية تقدمًا ملحوظًا منذ اكتشاف الفيروس قبل أكثر من 40 عامًا، ما مكّن الأشخاص المصابين بفيروس نقص المناعة البشرية من العيش حياة طويلة وصحية أثناء تلقي العلاج. إن ابتكار اختبار يمكنه اكتشاف كلتا العدوتين من عينة واحدة يساعد على ضمان وصول الكنديين إلى الرعاية بشكل سريع ومنصف. يعتبر اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis طريقة مبتكرة وفعالة لتوسيع نطاق الوصول إلى الاختبارات المبكرة والمنتظمة للعدوى المنقولة جنسياً والعدوى المنقولة عن طريق الدم في كندا.

صرح Mackie قائلًا “هناك حاجة ملحة لإجراء اختبار تشخيصي سريع وموثوق في ضوء ظهور مرض الزهري في كندا، فضلًا عن الزيادة المقلقة في الإصابة بمرض الزهري الخلقي”. وأضاف قائلًا “من خلال ابتكار اختبار دقيق للغاية ومبتكر مدته دقيقة واحدة، تتيح INSTI® للكنديين معرفة حالة إصابتهم باثنتين من العدوى بقطرة دم واحدة، وهو ما ساعد المزيد من الكنديين على إجراء الاختبار، ومعرفة حالة إصابتهم، والحصول على الرعاية.”

ستنتج شركة bioLytical اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis في برنامج التدقيق الفردي للأجهزة الطبية (MDSAP) الخاص بها: وهي منشأة حاصلة على شهادة الجودة أيزو ISO 13485 في كولومبيا البريطانية للبيع والتوزيع في جميع أنحاء كندا. بصفتها شركة عالمية رائدة في تشخيص الأمراض المعدية فائقة السرعة، تعمل bioLytical على ضمان توفر مجموعات الاختبار لدينا للكنديين ليتمكنوا من معرفة حالة إصابتهم.

هذا وتعتبر شركة bioLytical Laboratories Inc.‎ شركة قطاع خاص كندية تعمل في مجالات البحث والتطوير والتسويق التجاري للتشخيصات الطبية السريعة في المختبرات، باستخدام منصتها التكنولوجية INSTI®‎ وخط الفحوص السريعة iStatis. وفازت bioLytical بالعديد من الجوائز المحلية والصناعية، بما في ذلك مُصدِّر العام في 2019 في بريتش كولومبيا. لقد حزنا لقب الشركة التقنية الطبية النامية لهذا العام في مجال علوم الحياة في بريتش كولومبيا، كما وشكّلنا مادة إعلامية دسمة بصفتنا أسرع الشركات نموًا في بريتيش كولومبيا لست أعوام، ومن ذلك دخولنا في قائمة الشركات الأسرع نموًا في عام 2020 لصحيفة جلوب أنجد ميل. وقد انتقلت bioLytical إلى مقر أحدث وأكبر بكثير، في ريتشموند، كولومبيا البريطانية، في عام 2020 لاستيعاب النمو الكبير الذي حققه فريقنا. من خلال تقديم نتائج دقيقة في دقيقة واحدة أو أقل، تشتمل مجموعة INSTI® على اختبار الأجسام المضادة INSTI® HIV-1/HIV-2، واختبار INSTI® Multiplex HIV Syphilis، واختبار INSTI® HIV الذاتي، واختبار الأجسام المضادة لكوفيد-19 INSTI®‎، واختبار الأجسام المضادة INSTI® HCV. تطرح bioLytical منتجاتها للبيع في أوروبا وأمريكا الشمالية وأمريكا الجنوبية وأفريقيا وآسيا. وقد أطلقت bioLytical منصة iStatis في عام 2022، وهي منصتها الجديدة لاختبار الفحوص السريعة لتوفير إتاحة أكبر للاختبار في جميع أنحاء العالم.

ومن خلال تقديم نتائج دقيقة في الوقت الفعلي، تقدم INSTI® وiStatis نتائج مهمة للمختصين الطبيين والمرضى ومؤسسات الصحة العامة في جميع أنحاء العالم، كما وتعتبر شريكًا مهمًا في معالجة بعض أكثر تحديات الرعاية الصحية خطورة في العالم. تفضل بزيارة www.istatis.com و www.insti.com و www.biolytical.com للاطلاع على مزيد من المعلومات.

المراجع

CATIE: https://www.catie.ca/syphilis-0

PHAC: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-11-12-november-december-2022/infectious-congenital-syphilis-canada-2021.html PHAC: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html

تتوفر الصورة المرفقة بهذا الإعلان عبر الرابط https://prdesk.globenewswire.com/api/ResourceLibraryFile/DownloadFile?source=pnr&Id=4adaf035-89ca-428d-a01d-9bf5c3f05e4b

جهة الاتصال الإعلامي:

Stephanie Ritchie، أخصائية الاتصالات في شركة bioLytical

press@biolytical.com

‎+1-778-238-9340

GlobeNewswire Distribution ID 3511006

Posted on

LeddarTech Releases LeddarVision Premium Surround, Its Latest Low-Level Fusion and Perception Product, to Support Automotive Level 2/2+ ADAS Applications

LeddarTech’s award-winning LeddarVision solution

LeddarVision technology recognized at Tech.AD USA and CES 2023

QUEBEC CITY, March 27, 2023 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD software technology, announces its third product launch since December with the LeddarVision™ Surround (LVS-2+). This product is a comprehensive fusion and perception software stack to support premium surround-view L2/L2+ ADAS highway assistance and 5-star NCAP 2025/GSR 2022 safety applications.

LeddarVision Surround (LVS-2+) is the latest low-level sensor fusion and perception product built on LeddarTech’s award-winning LeddarVision software. The LVS-2+ expands the company’s current product offering of the LeddarVision Front-Entry LVF-E and Front-High LVF-H. These products target entry- to premium-level ADAS applications.

The LVS-2+ efficiently extends the LVF front-view product family from a one-camera plus two to five-radar (1V2R-1V5R) sensor configuration to a five-camera plus five-radar (5V5R) configuration. This enhanced configuration supports ADAS functions such as traffic jam and highway assist applications, enabling automated lane changes, overtaking and extended speed range adaptive cruise control.

High-Performance and Cost-Effective

  • LeddarVision’s low-level fusion (LLF) technology pushes the performance envelope, extending the effective range of the sensors.
  • Low-level fusion optimally combines camera and radar modalities, achieving a high-performance system with reduced requirements per modality at a lower total sensing cost.
  • Superior accuracy in object separation and longitudinal position measurement on highways enables higher-performing adaptive cruise control implementation.
  • L2/L2+ highway assist, including adaptive cruise control up to 160 km/h, lane centering control, active lane change assist, traffic jam assist and highway assist (including auto-lane change support).

Safety

  • LVS-2+ addresses 5-star NCAP 2025/GSR 2022 safety applications.
  • Includes a built-in redundancy feature to accommodate sensor failures, degradations and conflicts.
  • LVS-2+ supports global scene attributes detection for operational design domain (ODD) analysis, sensor coverage and health monitoring features.

Flexible and Scalable

  • A comprehensive surround-view fusion and perception software platform that supports entry-level to premium ADAS highway assist Level 2/2+ applications.

Samples available: Contact LeddarTech for “A” samples of the LVS-2+ and “A” samples of the LVF-E and LVF-H products. LVS-2+ “B” sample availability is planned for late Q3 2023.

“LeddarTech is committed to supporting automotive Tier 1-2 suppliers and OEMs with software solutions and products that support enhanced safety features and lower overall development costs,” stated the company’s CEO, Charles Boulanger. “In December, we released our LVF products for entry-level to premium ADAS safety and highway assistance L2/L2+ applications, and in keeping with our commitment to continual product development, our newest product LeddarVision Surround (LVS-2+) further increases our software offering to our customers, with products that solve more safety issues with a scalable low-level fusion and perception software stack that offers higher performance at a lower cost,” Mr. Boulanger concluded.

LeddarTech launches the LVS-2+ officially at Automotive Tech.AD Berlin on March 27, 2023.

About LeddarTech

LeddarTech, a global software company founded in 2007, develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving applications. LeddarTech’s automotive-grade software applies advanced AI and computer vision algorithms to generate highly accurate 3D models of the environment, allowing for better decision making and safer navigation. This high-performance, scalable, cost-effective technology is leveraged by OEMs and Tier 1-2 suppliers to efficiently implement automotive and off-road vehicle ADAS solutions.

LeddarTech is responsible for several remote-sensing innovations, with over 150 patents granted or applied for that enhance ADAS and AD capabilities. Better awareness around vehicle is critical in making global mobility safer, more efficient, sustainable and affordable: this is what drives LeddarTech to become the most widely adopted sensor fusion and perception software solution.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

Investor relations contact and website: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b7f20647-203a-42b4-b015-cedc2086ded5

GlobeNewswire Distribution ID 8793884

Posted on

A LeddarTech lança o LeddarVision Premium Surround, seu mais recente produto de fusão de baixo nível e percepção, para apoiar as aplicações ADAS de nível 2/2+ no setor automotivo

CIDADE DO QUEBEC, March 27, 2023 (GLOBE NEWSWIRE) — A LeddarTech®, líder mundial no fornecimento da mais flexível, robusta e precisa tecnologia de software ADAS e AD, anuncia seu terceiro lançamento de produtos desde dezembro com o LeddarVision™ Surround (LVS-2+). Esse produto é uma pilha de software abrangente de fusão e percepção para apoiar as aplicações de assistência rodoviária premium surround-view L2/L2+ ADAS e de segurança 5 estrelas NCAP 2025/GSR 2022.

O LeddarVision Surround (LVS-2+) é o mais recente produto de baixo nível de fusão de sensores e percepção desenvolvido sobre o premiado software LeddarVision da LeddarTech. O LVS-2+ amplia a oferta atual de produtos da empresa da LeddarVision Front-Entry LVF-E e Front-High LVF-H. Esses produtos visam a entrada em aplicações ADAS de nível premium.

O LVS-2+ amplia eficientemente a família de produtos LVF de uma configuração de sensores com uma câmera mais dois a cinco radares (1V2R-1V5R) para uma configuração de cinco câmeras mais cinco radares (5V5R). Essa configuração aprimorada compatível com as funções ADAS, tais como engarrafamentos de trânsito e aplicações de assistência rodoviária, permitindo mudanças automáticas de faixa, ultrapassagens e controle de velocidade de cruzeiro adaptativo à faixa ampliada.

Alto desempenho e econômico

  • A tecnologia de fusão de baixo nível da LeddarVision (LLF) impulsiona o desempenho envolvente, ampliando o alcance efetivo dos sensores.
  • A fusão de baixo nível combina perfeitamente as modalidades de câmera e radar, alcançando um sistema de alto desempenho com requisitos reduzidos por modalidade a um custo total de detecção mais baixo.
  • A precisão superior na separação de objetos e medição da posição longitudinal em rodovias permite uma implementação de controle de cruzeiro adaptativo de maior desempenho.
  • A assistência rodoviária L2/L2+, incluindo o controle adaptativo de cruzeiro até 160 km/h, controle de centralização de faixa, assistência ativa de mudança de faixa, assistência em engarrafamentos de trânsito e assistência rodoviária (incluindo suporte de mudança automática de pista).

Segurança

  • O LVS-2+ aborda as aplicações de segurança 5 estrelas NCAP 2025/GSR 2022.
  • Inclui uma funcionalidade de redundância incorporada para acomodar falhas nos sensores, degradações e conflitos.
  • O LVS-2+ é compatível com a detecção de atributos de panorama global para análise do domínio de design operacional (ODD), cobertura de sensores e funcionalidades de monitoramento de saúde.

Flexível e Escalável

  • Uma plataforma de software abrangente de fusão e percepção de visão circundante que é compatível com aplicações de nível 2/2+ de assistência rodoviária ADAS premium.

Amostras disponíveis: Contacte a LeddarTech para obter amostras “A” dos produtos LVS-2+ e amostras “A” dos produtos LVF-E e LVF-H. A disponibilidade de amostras “B” do LVS-2+ está planejada para o final do 3.º trimestre de 2023.

“A LeddarTech está comprometida em apoiar os fornecedores automotivos de nível 1-2 e OEMs com soluções e produtos de software que são compatíveis com recursos de segurança aprimorados e custos de desenvolvimento mais baixos”, declarou o CEO da empresa, Charles Boulanger. “Em dezembro, lançamos nossos produtos LVF para aplicações L2/L2+ de segurança e assistência rodoviária ADAS premium, e de acordo com nosso compromisso com o desenvolvimento contínuo de produtos, nosso mais novo produto LeddarVision Surround (LVS-2+) aumenta ainda mais nossa oferta de software para nossos clientes, com produtos que resolvem mais problemas de segurança com uma pilha de software escalável com fusão baixo nível e percepção que oferece maior desempenho a um custo menor”, concluiu o Sr. Boulanger.

A LeddarTech lança oficialmente o LVS-2+ na Automotive Tech.AD Berlim em 27 de março de 2023.

Sobre a LeddarTech

A LeddarTech, uma empresa global de software fundada em 2007, desenvolve e fornece soluções abrangentes de software de percepção que permitem a implantação de ADAS e aplicações de condução autônoma. O software de grau automotivo da LeddarTech aplica algoritmos avançados de IA e visão computadorizada para gerar modelos 3D altamente precisos do ambiente, permitindo uma melhor tomada de decisão e uma navegação mais segura. Essa tecnologia de alto desempenho, escalável e econômica é alavancada por OEMs e fornecedores de nível 1-2 para implementar eficientemente as soluções ADAS para veículos automotivos e off-road.

A LeddarTech é responsável por várias inovações de detecção remota, com mais de 150 patentes concedidas ou requeridas que melhoram as capacidades ADAS e AD. Uma melhor consciência em torno do veículo é fundamental para tornar a mobilidade global mais segura, mais eficiente, sustentável e acessível: isso é o que leva a LeddarTech a se tornar a solução de software de fusão de sensores e percepção mais amplamente adotada.

Informações adicionais sobre a LeddarTech estão acessíveis em www.leddartech.com e no LinkedIn, Twitter, Facebook e YouTube.

Contato:
Daniel Aitken, Vice-Presidente, Marketing Global, Comunicações e Relações com Investidores, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

Contato de Relações com Investidores e site: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision e os logotipos relacionados são marcas comerciais ou marcas registradas da LeddarTech Inc. e de suas filiais. Todas as outras marcas e nomes de produtos são ou podem ser marcas comerciais ou registradas usadas para identificar produtos ou serviços de seus respectivos proprietários.

A foto que acompanha este anúncio está disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/b7f20647-203a-42b4-b015-cedc2086ded5

GlobeNewswire Distribution ID 8793886